ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0959

Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score

Bich Na Choi1, Claudia Pedroza2, Brian Skaug3, Maureen Mayes4 and Shervin Assassi5, 1UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, 2UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UT Health Houston Division of Rheumatology, Houston, TX, 5Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX

Meeting: ACR Convergence 2025

Keywords: Gene Expression, proteomics, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot be done routinely, serum is collected for routine clinical care. Prior studies showed serum protein profiles align more with skin molecular changes than with peripheral blood cells (PBCs), though they analyzed a limited number of proteins. The current study characterizes longitudinal large-scale serum proteomic profile alongside global gene expression in PBCs and skin biopsies from SSc patients and healthy controls.

Methods: Three-level samples were collected from 109 SSc patients (disease duration < 6 year) and 42 matched controls. 98 SSc patients had a second sample and 47 had a third sample. 5416 serum proteins were measured using Olink Explore HT panel in serum samples. In addition, bulk global gene expression profiling was performed on concurrently collected skin and PBC RNA samples. An FDR adjusted p-value of 0.05 was considered statistically significant.

Results: The mean disease duration was 2.71 years and 61% of patients had diffuse SSc. In comparison of baseline SSc samples to controls, 697 proteins were significantly differentially expressed. Moreover, 249 proteins significantly correlated with modified Rodnan Skin Score (mRSS) (Figure 1A), of which 184 proteins were also differentially expressed in concordant direction in SSc vs control comparison (Figure 1B), indicating a significant correlation between direction of differential expression of serum proteins in SSc vs. control comparison and their association with mRSS (Figure 1C – permutation p-value < 0.0001 – Figure 1D). The differential expression of serum proteins in SSc vs. control comparison correlated more strongly with the differential expression of corresponding transcripts in skin than in PBCs (ρ=0.17 vs ρ=0.081, Figure 2). Similar to previously reported observations in skin, a comparison of the last to the initial serum samples in patients with early diffuse disease (n=36 – disease duration < 3 years) showed that the follow up serum samples clustered nearer to healthy controls than did initial serum samples (see the PCA analysis shown in Figure 3). Similar results were found when the skin transcriptomic and serum proteomic data were integrated using Similarity Network Fusion (SNF) analysis.Among differentially expressed serum proteins, 141 baseline protein levels (20.1%) showed predictive significance for the rate of longitudinal change in mRSS after adjustment for disease duration and gender among patients with diffuse systemic sclerosis (Figure 3C), with 23 proteins being associated with faster increases in mRSS while 118 proteins were associated with slower increase or even a decrease in mRSS over time.

Conclusion: SSc proteomic signature reflects more closely the molecular dysregulations of skin than PBC and shows a trend towards normalization, paralleling the findings at the skin transcriptomic level. Moreover, serum proteins are associated with rate of change in mRSS over time and might aid in identifying patients with rapidly progressing skin fibrosis.

Supporting image 1Figure 1. A) Volcano plot of differences between SSc-Controls; B) Volcano plot of the correlation between proteins and mRSS in SSc; C) Scatter plot of associations with mRSS and SSc-Controls differences; D) Permutation-based significance of correlation between differential serum protein expression (SSc vs. control) and its association with mRSS. The vertical red dashed line indicates the observed Spearman correlation coefficient based on the original sample annotation, while the histogram represents the null distribution of correlation values obtained from randomly permuted sample labels.

Supporting image 2Figure 2. Concordance of between-sample similarities, measured by Spearman correlations, for pairwise comparisons of protein expression between skin and PBC. The Mantel test’s observed concordance (vertical red dashed lines) was evaluated against null distributions created by random permutation of samples within each dataset.

Supporting image 3Figure 3. A) Principal component analysis (PCA) with differentially expressed serum proteins in healthy controls, first and last biopsies from early diffuse patients. B) Similarity Network Fusion (SNF) analysis of longitudinal serum protein and skin gene expression data from healthy controls and from the initial and final biopsies of early diffuse SSc patients. C) Volcano plot of serum proteins predictive of longitudinal mRSS change.


Disclosures: B. Choi: None; C. Pedroza: Medicem, 5; B. Skaug: None; M. Mayes: Argenx, 2, AstraZeneca, 5, atyr, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 1, 5, h, 5, Novartis, 2, prometheus merck, 5; S. Assassi: AbbVie, 2, AstraZeneca, 2, aTyr, 2, 5, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard, CSL Behring, 2, Janssen, 5, Merck, 2, Mitsubishi Tanabe, 2, PeerView Institute for Medical Education, 6, Scleroderma Research Foundation, 5, 6, Takeda, 2, TeneoFour, 2.

To cite this abstract in AMA style:

Choi B, Pedroza C, Skaug B, Mayes M, Assassi S. Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/longitudinal-multiomic-study-of-skin-peripheral-blood-and-serum-serum-proteome-reflects-the-disease-process-at-the-end-organ-level-and-predicts-the-course-of-modified-rodnan-skin-score/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-multiomic-study-of-skin-peripheral-blood-and-serum-serum-proteome-reflects-the-disease-process-at-the-end-organ-level-and-predicts-the-course-of-modified-rodnan-skin-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology